High-Dose Subcutaneous Administration of Biologics: Overcoming Barriers Through Formulation and Device Innovation
📄 英文摘要 English Abstract
The therapeutic landscape for biologics is rapidly transitioning from intravenous (IV) to subcutaneous (SC) administration, offering significant benefits in cost reduction and patient convenience through enabling treatment in flexible care settings. This shift necessitates patient-centric SC administration solutions. To address this, two primary innovative strategies are emerging: higher concentration formulations and large-volume SC (LVSC) injection/infusion. Ultra-high concentration biologic (UHCB) formulations, defined here as ≥250 g/L, are actively being pursued as suspensions. These UHCB suspension approaches rely on processing methods to entrap biologics within microparticles of a defined particle size (e.g., spray drying, electrospraying, solvent evaporation and dehydration, alginate, crystals). These UHCB suspension formulations are shear-thinning injectable drug product solutions. For LVSC administration, delivery is aided by co-formulating with hyaluronidase and/or utilizing on-body injectors (OBIs), high-volume autoinjectors (HVAI), or other administration equipment that reduces the treatment burden for healthcare professionals, caregivers, and patients. Despite promising preclinical data, the commercial translation of these platforms faces substantial hurdles, including establishing robust aseptic manufacturing processes for suspensions, developing specialized analytical control strategies, ensuring device compatibility (e.g., avoiding needle clogging), and navigating complex regulatory pathways requiring clinical bridging and comparability assessments. Continued collaborative efforts among industry and regulators will be essential to streamline development and realize patient-centric high-dose SC options.
📄 中文摘要 Chinese Abstract
📋 英文结构化总结 English Structured Summary
摘要整理
Background:
The therapeutic landscape for biologics is rapidly transitioning from intravenous (IV) to subcutaneous (SC) administration, offering significant benefits in cost reduction and patient convenience through enabling treatment in flexible care settings. This shift necessitates patient-centric SC administration solutions. To address this, two primary innovative strategies are emerging: higher concentration formulations and large-volume SC (LVSC) injection/infusion.
Methods:
Ultra-high concentration biologic (UHCB) formulations, defined here as ≥250 g/L, are actively being pursued as suspensions. These UHCB suspension approaches rely on processing methods to entrap biologics within microparticles of a defined particle size (e.g., spray drying, electrospraying, solvent evaporation and dehydration, alginate, crystals). For LVSC administration, delivery is aided by co-formulating with hyaluronidase and/or utilizing on-body injectors (OBIs), high-volume autoinjectors (HVAI), or other administration equipment.
Results:
These UHCB suspension formulations are shear-thinning injectable drug product solutions. Despite promising preclinical data, the commercial translation of these platforms faces substantial hurdles, including establishing robust aseptic manufacturing processes for suspensions, developing specialized analytical control strategies, ensuring device compatibility (e.g., avoiding needle clogging), and navigating complex regulatory pathways requiring clinical bridging and comparability assessments.
Data Summary:
The abstract defines UHCB formulations as ≥250 g/L and identifies two primary innovative strategies: higher concentration formulations and LVSC injection/infusion.
Conclusions:
Despite promising preclinical data, the commercial translation of these platforms faces substantial hurdles, including establishing robust aseptic manufacturing processes for suspensions, developing specialized analytical control strategies, ensuring device compatibility (e.g., avoiding needle clogging), and navigating complex regulatory pathways requiring clinical bridging and comparability assessments. Continued collaborative efforts among industry and regulators will be essential to streamline development and realize patient-centric high-dose SC options.
Practical Significance:
The transition from IV to SC administration offers significant benefits in cost reduction and patient convenience through enabling treatment in flexible care settings, while LVSC administration approaches reduce the treatment burden for healthcare professionals, caregivers, and patients.
📋 中文结构化总结 Chinese Structured Summary
背景:
生物制剂的治疗格局正从静脉给药（IV）快速转向皮下给药（SC），通过支持在灵活护理环境中进行治疗，在降低成本和提高患者便利性方面带来显著益处。这一转变需要以患者为中心的皮下给药解决方案。为此，两种主要的创新策略正在兴起：更高浓度制剂和大容量皮下（LVSC）注射/输注。
方法:
超高浓度生物制剂（UHCB）制剂（此处定义为≥250 g/L）正作为悬浮剂被积极开发。这些UHCB悬浮剂方案依赖于加工方法，将生物制剂包埋于具有规定粒径的微粒中（例如喷雾干燥、静电喷雾、溶剂蒸发与脱水、海藻酸盐、晶体）。对于LVSC给药，可通过与透明质酸酶共配制和/或使用贴体注射器（OBIs）、大容量自动注射器（HVAI）或其他给药装置来辅助递送。
结果:
这些UHCB悬浮剂制剂是剪切变稀的可注射药物产品溶液。尽管临床前数据令人鼓舞，但这些平台的商业化转化仍面临重大障碍，包括建立稳健的悬浮剂无菌生产工艺、开发专门的分析控制策略、确保装置相容性（例如避免针头堵塞），以及应对需要临床桥接和可比性评估的复杂监管路径。
数据摘要:
本摘要将UHCB制剂定义为≥250 g/L，并指出两种主要创新策略：更高浓度制剂和LVSC注射/输注。
结论:
尽管临床前数据令人鼓舞，但这些平台的商业化转化仍面临重大障碍，包括建立稳健的悬浮剂无菌生产工艺、开发专门的分析控制策略、确保装置相容性（例如避免针头堵塞），以及应对需要临床桥接和可比性评估的复杂监管路径。产业界与监管机构之间持续的协作对于简化开发流程并实现以患者为中心的大剂量皮下给药方案至关重要。
实践意义:
从静脉给药转向皮下给药，通过支持在灵活护理环境中进行治疗，在降低成本和提高患者便利性方面具有显著益处；同时，LVSC给药方案可降低医疗专业人员、照护者和患者的治疗负担。